Robust outreach and enrollment efforts, and standards and payments that ensure timely and equitable access to quality care are critical to a comprehensive access and coverage strategy, AHA told (LINK to come) the Centers for Medicare & Medicaid Services today, responding to the agency’s recent request for information on the issue.

“State governments’ chronic underfunding of the program, and the added pressure for states, hospitals and others providers in managing the ongoing COVID-19 pandemic, present significant challenges for CMS in developing comprehensive solutions to ensure access and coverage,” the letter notes. “The AHA recommends that the agency convene stakeholder roundtables or workgroups to explore regulatory and legislative solutions to these access and coverage challenges and ensure that both beneficiaries and their hospital and health system providers are represented.” 

CMS plans to use stakeholder feedback on the RFI to inform future policies, monitoring and regulatory actions to ensure Medicaid and CHIP beneficiaries have equitable access to high quality and appropriate care.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
The AHA Dec. 19 submitted comments on the Department of Homeland Security’s proposed rule regarding the Public Charge Ground of Inadmissibility, urging the…
Headline
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
The House Dec. 17 passed the Lower Health Care Premiums for All Americans Act (H.R. 6703), legislation to expand association health plans, increase…
Headline
The AHA Dec. 17 urged Elevance Health, which is the parent company of the Anthem brand of health plans, to rescind Anthem’s nonparticipating provider…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…